Results 191 to 200 of about 29,072 (265)

A Framework for Emergency Department–Integrated Hepatitis C Test‐and‐Treat in the United States

open access: yesJournal of Viral Hepatitis, Volume 33, Issue 6, June 2026.
ABSTRACT Despite the availability of curative, direct‐acting antiviral therapy, hepatitis C virus elimination remains incomplete. Losses across the care cascade continue to limit impact, from initial diagnosis to sustained virologic response. Fewer than 1/3 of individuals ultimately achieve cure. These gaps reflect a delivery system that does not align
Saeed S. Graham
wiley   +1 more source

Clinical Conditions Associated With a High Antinuclear Antibody Titer in Individuals Without Autoimmune Disease

open access: yesArthritis Care &Research, Volume 78, Issue 5, Page 662-669, May 2026.
Objective Antinuclear antibodies (ANAs) are present at high titers in 2% of the general population, but their clinical significance in individuals without an autoimmune (AI) disease is not known. We tested the hypothesis that the presence of a high ANA titer in non‐AI conditions is associated with disease.
Matthew Chung   +7 more
wiley   +1 more source

Liver Stiffness Directs Intrahepatic Cholesterol Accumulation Through YAP/TAZ in Metabolic Dysfunction‐Associated Steatotic Liver Disease

open access: yesAdvanced Science, Volume 13, Issue 25, 4 May 2026.
Liver stiffness promotes intrahepatic cholesterol accumulation by repressing LXRα through YAP/TAZ activation. Stiff matrices impair cholesterol efflux in hepatocytes, while YAP/TAZ deletion restores LXRα activity and prevents cholesterol‐induced fibrosis.
Na Young Lee   +9 more
wiley   +1 more source

Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Chinese Retrospective Multicenter Study Based on Global Meta‐Analysis

open access: yesCancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Objective Microvascular invasion (MVI) has been identified as a risk factor for the prognosis of patients with hepatocellular carcinoma (HCC). However, it can only be diagnosed pathologically, and thus no widely applicable preoperative MVI risk prediction model has been established.
Jia Xu   +10 more
wiley   +1 more source

Fitusiran treatment modulates the ratio between alpha‐ and beta‐antithrombin isoforms

open access: yesHemaSphere, Volume 10, Issue 5, May 2026.
Abstract Antithrombin (AT) circulates as two distinct isoforms, alpha‐ and beta‐AT, which differ in their glycosylation profiles; alpha‐AT is fully glycosylated at positions Asn128, Asn167, Asn187, and Asn224, whereas beta‐AT lacks Asn167 glycosylation.
Geneviève McCluskey   +10 more
wiley   +1 more source

Epidemiology, Risk Factors and Pathophysiology of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease: An Update

open access: yesJCC Plus, Volume 1, Issue 3, May 2026.
ABSTRACT Background and Aims Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) represent a unique clinical syndrome affecting up to 80% of PSC patients, characterised by distinct epidemiological patterns, pathophysiological mechanisms and clinical outcomes that differ substantially from either condition occurring independently ...
Luisa Bertin   +7 more
wiley   +1 more source

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou   +10 more
wiley   +1 more source

2025 Consensus Clinical Management Guidelines for Niemann‐Pick Disease Type C

open access: yesJournal of Inherited Metabolic Disease, Volume 49, Issue 3, May 2026.
ABSTRACT In 2018, the International Niemann‐Pick Disease Alliance (INPDA) and the International Niemann‐Pick Disease Registry (INPDR) developed and published comprehensive clinical management guidelines to support inclusive and standardized care pathways in Niemann‐Pick disease type C (NPC)—an ultra‐rare, autosomal recessive, neurovisceral lysosomal ...
Tarekegn Hiwot   +33 more
wiley   +1 more source

Home - About - Disclaimer - Privacy